CHALFONT ST GILES, UK, - GE Healthcare has announced the introduction of Ettan nanoLC, a fully bio-inert, robust, nanoscale peptide separation system that delivers highly reproducible performance and is ideal for 1D-liquid chromatography (LC) proteomics applications upstream from electrospray ionization mass spectrometry (MS) or MALDI MS/MS applications.

The nanoLC extends the range of applications of GE Healthcares popular family of Ettan chromatography systems, which includes Ettan LC system, Ettan microLC, and Ettan MDLC multidimensional liquid chromatography system. The nano LC is ideally suited for those with limited funding requiring a dedicated 1DLC system who dont want to compromise on the high sensitivity enabled by our LC platform.

The Ettan nano LC performs high-pressure gradient formation with unmatched reproducibility and online, real-time gradient monitoring, while maintaining a continuous flow to the ion source or MALDI spotter throughout a run. The instruments low dead volumes ensure minimum peak broadening and consistent peak concentrations for maximum sensitivity and resolution.
The Ettan nanoLC platform includes the high quality components GE Healthcare customers have come to value in our KTA chromatography systems, says Jasmine Gruia-Gray, global marketing director, Protein Discovery at GE Healthcare. The bio-inert system offers unique advantages for peptide separation of labile phosphopeptides upstream from electrospray ionization MS.

Integrated system components include a flow splitter that ensures excellent gradient elution at flow rates as low as 200 nl/min, UV and conductivity monitors, the P-905 pump, a pressure sensor, and biocompatible flow path and pump heads. The Peltier-cooled Autosampler A-905 allows injection of as little as 100 nl of sample from vials or microtiter plates.

Control and evaluation of the chromatographic process can be achieved using GE Healthcares robust and easy-to-use UNICORN software or via a virtual interface with the MS software module.

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform and treat disease, so their patients can live their lives to the fullest.

GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases, and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention.

Headquartered in the United Kingdom, GE Healthcare is a $15 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 43,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

More Industry Headlines